Shopping Cart 0
Cart Subtotal
USD 0

Wounds-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Wounds-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Wounds-Pipeline Review, H2 2017, provides an overview of the Wounds (Dermatology) pipeline landscape.

Wound is a breakdown in the protective function of the skin (the loss of continuity of epithelium) with or without loss of underlying connective tissue (i.e. muscle, bone, nerves) following injury to the skin or underlying tissues/ organs caused by surgery, a blow, a cut, chemicals, heat/ cold, friction/ shear force, pressure or as a result of disease, such as leg ulcers or carcinomas. Signs and symptoms include redness or red streaks on the skin surrounding the wound, increased swelling to tenderness at the wound site, pus-like drainage or a foul smell from the wound and body chills or fever.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Wounds-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Wounds (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Wounds (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Wounds and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 4, 8, 1, 56, 7 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 12 and 6 molecules, respectively.

Wounds (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Wounds (Dermatology).

The pipeline guide reviews pipeline therapeutics for Wounds (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Wounds (Dermatology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Wounds (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Wounds (Dermatology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Wounds (Dermatology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it'smost promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Wounds (Dermatology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents

Introduction

Wounds-Overview

Wounds-Therapeutics Development

Wounds-Therapeutics Assessment

Wounds-Companies Involved in Therapeutics Development

Wounds-Drug Profiles

Wounds-Dormant Projects

Wounds-Discontinued Products

Wounds-Product Development Milestones

Appendix


List Of Figure

List of Figures

Number of Products under Development for Wounds, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Wounds, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Wounds-Pipeline by Advanced Inhalation Therapies (AIT) Ltd, H2 2017

Wounds-Pipeline by AlgiPharma AS, H2 2017

Wounds-Pipeline by Alliance Pharma Plc, H2 2017

Wounds-Pipeline by AmpliPhi Biosciences Corp, H2 2017

Wounds-Pipeline by AndroScience Corp, H2 2017

Wounds-Pipeline by Aridis Pharmaceuticals LLC, H2 2017

Wounds-Pipeline by Beech Tree Labs Inc, H2 2017

Wounds-Pipeline by Bioblue Technologies Inc, H2 2017

Wounds-Pipeline by Biotec Pharmacon ASA, H2 2017

Wounds-Pipeline by Cellphire Inc, H2 2017

Wounds-Pipeline by Chiesi Farmaceutici SpA, H2 2017

Wounds-Pipeline by CorMedix Inc, H2 2017

Wounds-Pipeline by CytoTools AG, H2 2017

Wounds-Pipeline by Dermala Inc, H2 2017

Wounds-Pipeline by Destiny Pharma Ltd, H2 2017

Wounds-Pipeline by Escape Therapeutics Inc, H2 2017

Wounds-Pipeline by Exicure Inc, H2 2017

Wounds-Pipeline by Exogenus Therapeutics SA, H2 2017

Wounds-Pipeline by FibroGen Inc, H2 2017

Wounds-Pipeline by Gene Signal International SA, H2 2017

Wounds-Pipeline by GlaxoSmithKline Plc, H2 2017

Wounds-Pipeline by IC-MedTech Inc, H2 2017

Wounds-Pipeline by Living Cell Technologies Ltd, H2 2017

Wounds-Pipeline by Madam Therapeutics BV, H2 2017

Wounds-Pipeline by MediWound Ltd, H2 2017

Wounds-Pipeline by Miragen Therapeutics Inc, H2 2017

Wounds-Pipeline by NatureWise Biotech & Medicals Corp, H2 2017

Wounds-Pipeline by Nippon Chemiphar Co Ltd, H2 2017

Wounds-Pipeline by Novan Inc, H2 2017

Wounds-Pipeline by Octapharma AG, H2 2017

Wounds-Pipeline by Omeros Corp, H2 2017

Wounds-Pipeline by Osiris Therapeutics Inc, H2 2017

Wounds-Pipeline by Pacific Northwest Biotechnology LLC, H2 2017

Wounds-Pipeline by ProMetic Life Sciences Inc, H2 2017

Wounds-Pipeline by SomaGenics Inc, H2 2017

Wounds-Pipeline by Stratatech Corp, H2 2017

Wounds-Pipeline by Synedgen Inc, H2 2017

Wounds-Pipeline by Thesan Pharmaceuticals Inc, H2 2017

Wounds-Pipeline by Topadur Pharma AG, H2 2017

Wounds-Pipeline by Traverse Biosciences Inc, H2 2017

Wounds-Pipeline by Tumorend LLC, H2 2017

Wounds-Pipeline by Vascular BioSciences, H2 2017

Wounds-Pipeline by viDA Therapeutics Inc, H2 2017

Wounds-Dormant Projects, H2 2017

Wounds-Dormant Projects, H2 2017 (Contd..1), H2 2017

Wounds-Dormant Projects, H2 2017 (Contd..2), H2 2017

Wounds-Dormant Projects, H2 2017 (Contd..3), H2 2017

Wounds-Dormant Projects, H2 2017 (Contd..4), H2 2017

Wounds-Dormant Projects, H2 2017 (Contd..5), H2 2017

Wounds-Discontinued Products, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

Advanced Inhalation Therapies (AIT) Ltd

AlgiPharma AS

Alliance Pharma Plc

AmpliPhi Biosciences Corp

AndroScience Corp

Aridis Pharmaceuticals LLC

Beech Tree Labs Inc

Bioblue Technologies Inc

Biotec Pharmacon ASA

Cellphire Inc

Chiesi Farmaceutici SpA

CorMedix Inc

CytoTools AG

Dermala Inc

Destiny Pharma Ltd

Escape Therapeutics Inc

Exicure Inc

Exogenus Therapeutics SA

FibroGen Inc

Gene Signal International SA

GlaxoSmithKline Plc

IC-MedTech Inc

Living Cell Technologies Ltd

Madam Therapeutics BV

MediWound Ltd

Miragen Therapeutics Inc

NatureWise Biotech & Medicals Corp

Nippon Chemiphar Co Ltd

Novan Inc

Octapharma AG

Omeros Corp

Osiris Therapeutics Inc

Pacific Northwest Biotechnology LLC

ProMetic Life Sciences Inc

SomaGenics Inc

Stratatech Corp

Synedgen Inc

Thesan Pharmaceuticals Inc

Topadur Pharma AG

Traverse Biosciences Inc

Tumorend LLC

Vascular BioSciences

viDA Therapeutics Inc

Wounds-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Wounds-Pipeline Review, H2 2017, provides an overview of the Wounds (Dermatology) pipeline landscape.

Wound is a breakdown in the protective function of the skin (the loss of continuity of epithelium) with or without loss of underlying connective tissue (i.e. muscle, bone, nerves) following injury to the skin or underlying tissues/ organs caused by surgery, a blow, a cut, chemicals, heat/ cold, friction/ shear force, pressure or as a result of disease, such as leg ulcers or carcinomas. Signs and symptoms include redness or red streaks on the skin surrounding the wound, increased swelling to tenderness at the wound site, pus-like drainage or a foul smell from the wound and body chills or fever.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Wounds-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Wounds (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Wounds (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Wounds and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 4, 8, 1, 56, 7 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 12 and 6 molecules, respectively.

Wounds (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Wounds (Dermatology).

The pipeline guide reviews pipeline therapeutics for Wounds (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Wounds (Dermatology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Wounds (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Wounds (Dermatology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Wounds (Dermatology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it'smost promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Wounds (Dermatology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents

Introduction

Wounds-Overview

Wounds-Therapeutics Development

Wounds-Therapeutics Assessment

Wounds-Companies Involved in Therapeutics Development

Wounds-Drug Profiles

Wounds-Dormant Projects

Wounds-Discontinued Products

Wounds-Product Development Milestones

Appendix


List Of Figure

List of Figures

Number of Products under Development for Wounds, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Wounds, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Wounds-Pipeline by Advanced Inhalation Therapies (AIT) Ltd, H2 2017

Wounds-Pipeline by AlgiPharma AS, H2 2017

Wounds-Pipeline by Alliance Pharma Plc, H2 2017

Wounds-Pipeline by AmpliPhi Biosciences Corp, H2 2017

Wounds-Pipeline by AndroScience Corp, H2 2017

Wounds-Pipeline by Aridis Pharmaceuticals LLC, H2 2017

Wounds-Pipeline by Beech Tree Labs Inc, H2 2017

Wounds-Pipeline by Bioblue Technologies Inc, H2 2017

Wounds-Pipeline by Biotec Pharmacon ASA, H2 2017

Wounds-Pipeline by Cellphire Inc, H2 2017

Wounds-Pipeline by Chiesi Farmaceutici SpA, H2 2017

Wounds-Pipeline by CorMedix Inc, H2 2017

Wounds-Pipeline by CytoTools AG, H2 2017

Wounds-Pipeline by Dermala Inc, H2 2017

Wounds-Pipeline by Destiny Pharma Ltd, H2 2017

Wounds-Pipeline by Escape Therapeutics Inc, H2 2017

Wounds-Pipeline by Exicure Inc, H2 2017

Wounds-Pipeline by Exogenus Therapeutics SA, H2 2017

Wounds-Pipeline by FibroGen Inc, H2 2017

Wounds-Pipeline by Gene Signal International SA, H2 2017

Wounds-Pipeline by GlaxoSmithKline Plc, H2 2017

Wounds-Pipeline by IC-MedTech Inc, H2 2017

Wounds-Pipeline by Living Cell Technologies Ltd, H2 2017

Wounds-Pipeline by Madam Therapeutics BV, H2 2017

Wounds-Pipeline by MediWound Ltd, H2 2017

Wounds-Pipeline by Miragen Therapeutics Inc, H2 2017

Wounds-Pipeline by NatureWise Biotech & Medicals Corp, H2 2017

Wounds-Pipeline by Nippon Chemiphar Co Ltd, H2 2017

Wounds-Pipeline by Novan Inc, H2 2017

Wounds-Pipeline by Octapharma AG, H2 2017

Wounds-Pipeline by Omeros Corp, H2 2017

Wounds-Pipeline by Osiris Therapeutics Inc, H2 2017

Wounds-Pipeline by Pacific Northwest Biotechnology LLC, H2 2017

Wounds-Pipeline by ProMetic Life Sciences Inc, H2 2017

Wounds-Pipeline by SomaGenics Inc, H2 2017

Wounds-Pipeline by Stratatech Corp, H2 2017

Wounds-Pipeline by Synedgen Inc, H2 2017

Wounds-Pipeline by Thesan Pharmaceuticals Inc, H2 2017

Wounds-Pipeline by Topadur Pharma AG, H2 2017

Wounds-Pipeline by Traverse Biosciences Inc, H2 2017

Wounds-Pipeline by Tumorend LLC, H2 2017

Wounds-Pipeline by Vascular BioSciences, H2 2017

Wounds-Pipeline by viDA Therapeutics Inc, H2 2017

Wounds-Dormant Projects, H2 2017

Wounds-Dormant Projects, H2 2017 (Contd..1), H2 2017

Wounds-Dormant Projects, H2 2017 (Contd..2), H2 2017

Wounds-Dormant Projects, H2 2017 (Contd..3), H2 2017

Wounds-Dormant Projects, H2 2017 (Contd..4), H2 2017

Wounds-Dormant Projects, H2 2017 (Contd..5), H2 2017

Wounds-Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Companies

Advanced Inhalation Therapies (AIT) Ltd

AlgiPharma AS

Alliance Pharma Plc

AmpliPhi Biosciences Corp

AndroScience Corp

Aridis Pharmaceuticals LLC

Beech Tree Labs Inc

Bioblue Technologies Inc

Biotec Pharmacon ASA

Cellphire Inc

Chiesi Farmaceutici SpA

CorMedix Inc

CytoTools AG

Dermala Inc

Destiny Pharma Ltd

Escape Therapeutics Inc

Exicure Inc

Exogenus Therapeutics SA

FibroGen Inc

Gene Signal International SA

GlaxoSmithKline Plc

IC-MedTech Inc

Living Cell Technologies Ltd

Madam Therapeutics BV

MediWound Ltd

Miragen Therapeutics Inc

NatureWise Biotech & Medicals Corp

Nippon Chemiphar Co Ltd

Novan Inc

Octapharma AG

Omeros Corp

Osiris Therapeutics Inc

Pacific Northwest Biotechnology LLC

ProMetic Life Sciences Inc

SomaGenics Inc

Stratatech Corp

Synedgen Inc

Thesan Pharmaceuticals Inc

Topadur Pharma AG

Traverse Biosciences Inc

Tumorend LLC

Vascular BioSciences

viDA Therapeutics Inc

chat_bubbleLet's Chat